Request Demo

Last update 24 Feb 2026

Dexamethasone Sodium Phosphate

Last update 24 Feb 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Dex 21-P, Dexamethasone 21-Phosphate, eDSP

+ [23]

Target

Action

agonists

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [10]

Active Indication

Brain EdemaCOVID-19Respiratory Distress Syndrome, Acute+ [38]

Inactive Indication

AnaphylaxisCataractChronic Limb-Threatening Ischemia+ [21]

Originator Organization

Merck & Co., Inc.

Active Organization

AVM Biotechnology LLC

Quince Therapeutics, Inc.

Hameln pharma Gmbh.

+ [8]

Inactive Organization

Semnur, Inc.

Kiora Pharmaceuticals, Inc.

Mercator MedSystems, Inc.

+ [5]

License Organization

Taiwan Liposome Co., Ltd.

Bausch Health Cos., Inc.

Endo International Plc

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (26 Aug 1959)

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaC22H30FNaO8P

InChIKeyVIKBYTWZYXGHAT-WKSAPEMMSA-N

CAS Registry2392-39-4

2,717

Clinical Trials associated with Dexamethasone Sodium Phosphate

NCT04366115

/ Not yet recruitingPhase 1

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study Evaluating AVM0703 in Patients With Acute Respiratory Distress Syndrome

This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose of AVM0703 in these ARDS patients.

Start Date01 Dec 2026

Sponsor / Collaborator

AVM Biotechnology LLC

[+1]

NCT07343817

/ Not yet recruitingEarly Phase 1IIT

Ultrasonic Evaluation of Metoclopramide With or Without Dexamethasone on Gastric Motility in Traumatic Patients

Reflux and the aspiration of gastric contents have always been important focal points. Previous study stated that trauma is an important factor in aspiration pneumonia.
Often, emergency trauma patients have residual gastric contents due to the ingestion of food before injury, the accidental swallowing of nasal and/or oral blood after injury, and delayed gastric emptying due to stress, pain, or the use of opioids.
During sedation or general anesthesia, such satiated patients are often at risk of aspiration due to a reduction in lower esophageal sphincter tension and the protective inhibition of the airway reflex.
Perioperative gastric ultrasound can be performed at a bedside ultrasound unit; it can safely, non-invasively, conveniently, and effectively evaluate the fullness of a patient's stomach and the nature of their gastric contents.
It can also be used in the selection of an appropriate method for the anesthetic induction process and can reduce the risk of vomiting, aspiration, and related complications.
As a gastric motility-promoting drug, metoclopramide can accelerate gastric emptying.
Dexamethasone reduced the incidence of nausea and vomiting and improve gastric motility.

Start Date01 Jul 2026

Sponsor / Collaborator

Assiut University

[+1]

NCT06348147

/ SuspendedPhase 2

An Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Stem Cell Transplantation

This Phase II hybrid decentralized trial will examine the effect of daratumumab-based quadruplet induction therapy administered at an attenuated schedule in subjects with newly diagnosed multiple myeloma (NDMM) who are eligible for standard-of-care autologous stem cell transplantation (ASCT). Daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVd) have recently become a standard induction regimen for patients with NDMM who are eligible for ASCT in the United States. As implemented in clinical trials, Dara-RVd involves twice weekly bortezomib administration, which is inconvenient for patients and may result in increased rates of limiting toxicity, such as peripheral neuropathy. Adoption of alternate schedules involving once-weekly bortezomib is common in real-world practice, however a paucity of prospective data supporting this practice exists.
This study examines the efficacy of an attenuated Dara-RVd schedule involving once-weekly bortezomib dosing.

Start Date01 Jul 2026

Sponsor / Collaborator

Lineberger Comprehensive Cancer Center

100 Clinical Results associated with Dexamethasone Sodium Phosphate

100 Translational Medicine associated with Dexamethasone Sodium Phosphate

100 Patents (Medical) associated with Dexamethasone Sodium Phosphate

1,843

Literatures (Medical) associated with Dexamethasone Sodium Phosphate

01 Jan 2026·Orthopaedic Journal of Sports Medicine

Regional Anesthesia Utilizing Liposomal Bupivacaine, With or Without Dexamethasone, Provides Excellent Pain Control and Minimizes Opioid Consumption Following Anterior Cruciate Ligament Reconstruction

Article

Author: Ciccotti, Michael G. ; Voskeridjian, Armen ; Dodson, Christopher C. ; Johns, William L. ; Muchintala, Rahul ; Miltenberg, Benjamin ; Cohen, Steven B. ; Salvo, John ; Hammoud, Sommer ; Sherman, Matthew

Background::

Perioperative nerve blocks are commonly used for regional analgesia with anterior cruciate ligament (ACL) reconstruction (ACLR). Liposomal bupivacaine (LB) is a long-acting anesthetic agent providing up to 72 hours of nerve blockade. It is theorized that the addition of dexamethasone to LB (LB+dex) may prolong the analgesic duration.

Purpose::

To characterize pain control and opioid consumption with adductor canal block (ACB), interspace between the popliteal artery and capsule of the posterior knee (iPACK), and suprasartorial infiltration (SSI) regional anesthetic techniques utilizing LB after ACLR and to compare LB versus LB+dex.

Study Design::

Randomized controlled trial; Level of evidence, 1.

Methods::

Patients undergoing primary ACLR using bone–patellar tendon–bone or quadriceps tendon autograft were included. All patients received an ACB, iPACK, and SSI preoperatively. Patients were randomized to receive either LB or LB+dex for their anesthetic agent. Opioid consumption, visual analog scale (VAS) scores, pain control satisfaction, and duration of block effect were recorded postoperatively.

Results::

A total of 131 patients were included in the analysis. The mean opioid consumption for all patients was 1.20 ± 2.42 five-mg oxycodone tablets (8.97 ± 18.12 morphine milliequivalents [MME]). We did not observe a significant difference in oxycodone consumption between cohorts during the study period (1.42 ± 2.92 vs 0.97 ± 1.91; 10.65 ± 21.90 MME vs 7.28 ± 14.33 MME; P = .76). An estimated 95.2% of opioids prescribed went unused and 77.1% (101/131) of patients consumed no opioids. There was no significant difference in VAS score, patient satisfaction, or duration of block effect between cohorts.

Conclusion::

A single shot of LB with or without dexamethasone via ACB, SSI, and iPACK block provided excellent pain control and minimized opioid consumption after autograft ACLR. Nearly 80% of patients did not require opioids postoperatively, making opioid-free ACLR a realistic possibility for many patients. When narcotics were required, the dose of opioids was minimal; patients required 1.2 tablets of oxycodone on average, and >95% of the opioids prescribed went unused. Despite previous reports suggesting a prolonged duration of anesthetic effect when LB is combined with dexamethasone, we found no difference in opioid consumption, VAS score, patient satisfaction, or duration of block effect when patients received dexamethasone with their regional block. The utilization of regional anesthetic techniques such as ACB, SSI, and iPACK blocks in conjunction with LB-based anesthetics could allow providers to curtail or potentially eliminate opioid prescriptions after ACL surgery.

Registration::

NCT06006624 (ClinicalTrials.gov identifier).

01 Dec 2025·VETERINARY DERMATOLOGY

Chemical Stability of Ceftazidime Compounded in Saline, Glycerin and Dexamethasone‐ SP Solutions Stored at −20°C, 4°C and 25°C Over a 60 Day Period

Article

Author: Tsai, Will ; Gustafson, Daniel ; Daniels, Joshua B. ; Banks, Krista ; Hoppers, Sarrah ; Bachtel, Jeremy ; Snidow, McKenna

ABSTRACT:

Background:

Chronic cases of canine otitis externa (OE) often develop infections with Pseudomonas aeruginosa (PA). Given the organism's high level of resistance, veterinary surgeons often turn to compounded solutions. Limited data describing the stability and potency of compounded ceftazidime (CAZ) solutions are available, which may affect clinical outcome.

Hypothesis/Objectives:

To evaluate the chemical stability of compounded glycerin (GLY) and dexamethasone sodium phosphate (DEX‐SP) CAZ solutions in three different storage temperatures over a 60‐day period. Based on previous evaluations, CAZ concentrations would decrease with increased temperature and time.

Materials and Methods:

Ceftazidime was compounded at 10 mg/mL with 100 mL 0.9% sodium chloride (NA + CAZ), 100 mL glycerin +0.9% sodium chloride (GLY + CAZ) and 100 mL dexamethasone sodium phosphate +0.9% sodium chloride (DEX‐SP + CAZ), stored at −20°C, 4°C and 25°C for 60 days. Mass spectrometry was used to analyse CAZ stability at specific time points (Day[D]0, D7, D14, D28, D60).

Results:

Chemical stability of CAZ concentrations was affected by storage time, temperature and diluent. CAZ concentrations decreased over time with increased temperature; frozen CAZ concentrations remained stable over time for all solutions.

Conclusions and Clinical Relevance:

Compounded CAZ stability varies by diluent, storage temperature and storage duration. NA + CAZ and DEX‐SP + CAZ solutions are stable for ≤ 28 days refrigerated and retain potency for ≥ 60 days if stored frozen. These solutions offer alternative options for treatment of PA OE.

01 Nov 2025·Biomedical Journal

HIF-1 AND DEC-1 LEVELS IN ACUTE ISCHAEMIC STROKE PATIENTS: COULD DEC-1 BE A NEW BIOMARKER IN STROKE?

Article

Author: Bilge, Nuray ; Demirdöğen, Filiz ; Eren, Alper

BACKGROUND /OBJECTIVES:

Although the underlying cause of ischemic stroke is vascular occlusion, the post-stroke pathophysiology remains unclear. Therefore, numerous biomarkers have been investigated for both diagnostic and prognostic purposes. In our study, the diagnostic value of the parameters NLR, PLR, RDW-CV, RDW-SD, HIF-1, and DEC-1 was comprehensively evaluated.

METHODS:

NLR, Blood samples from patients with ischemic stroke and healthy controls were analyzed for NLR, PLR, RDW-CV, RDW-SD, HIF-1, and DEC-1 levels. Demographic and clinical characteristics of both patient and control groups were recorded. The relationship between HIF-DEC measurements and laboratory parameters was subsequently assessed. For statistical analysis, the Mann-Whitney U test was used for comparisons between groups, and the Chi-Square test was applied for categorical variables.

RESULTS:

RDW-SD values were found to be higher in patients diagnosed with cerebrovascular accident (CVA) while DEC levels were lower in the stroke group. Although no significant correlation was observed between HIF levels and other parameters in either the CVA or control groups, there was a weak inverse correlation found between DEC and NLR (r:-0.258), and between DEC and RDW-CV (r:-0.268), and a weak linear correlation between DEC and RDW (r:0.319) in the whole group. No significant correlations were found between DEC and other measurements within either the control or CVA groups individually.

CONCLUSIONS:

Our study may indicate that pathways increasing the levels of DEC-1, which acts on the PI3K/Akt pathway, could lead the development of new therapeutic strategies for ischemic stroke.

296

News (Medical) associated with Dexamethasone Sodium Phosphate

23 Feb 2026

·www.biospace.com

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM). “Initiating the Phase 2 MOMENTUM trial, which builds upon the compelling anti-myeloma activity and differentiated safety pro in the Phase 1 trial, is a critical step for cemsidomide to become a foundational therapy for multiple myeloma patients, who are in need of a safe, oral, and convenient treatment option,” said Len Reyno, chief medical officer of C4 Therapeutics. “With this milestone accomplished, we are also on track to initiate the Phase 1b trial of cemsidomide in combination with elranatamab in the second quarter, as we continue to advance our regulatory strategy that could deliver two accelerated approval paths in multiple myeloma.” The Phase 2 MOMENTUM trial is an open-label, single-arm, multicenter study to assess anti-myeloma activity and further characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of cemsidomide, an oral IKZF1/3 degrader, in combination with dexamethasone in RRMM patients for the fourth line or later. The trial will enroll approximately 100 patients to evaluate cemsidomide at the 100 µg dose level. Cemsidomide is administered with a daily dosing schedule of 14 days on and 14 days off, and dexamethasone is dosed once a week. The primary endpoint is the overall response rate per the International Myeloma Working Group response criteria as assessed by an independent review committee. Secondary endpoints will evaluate a range of additional safety and efficacy measures. The Phase 2 MOMENTUM trial is part of a broader development strategy for cemsidomide, which also includes a Phase 1b study of cemsidomide in combination with elranatamab (ELREXFIO ® ). Elranatamab is an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody. Together, these trials support cemsidomide’s use across multiple lines of treatment. ANTICIPATED UPCOMING MILESTONES Phase 1b trial of cemsidomide in combination with elranatamab is on track to initiate in Q2 2026. Further analysis of the completed Phase 1 trial of cemsidomide in combination with dexamethasone is expected in mid-2026. Enrollment for Phase 2 MOMENTUM trial is expected to be completed in Q1 2027. About Cemsidomide Cemsidomide is an investigational, orally bioavailable molecular glue degrader (MonoDAC ® degrader) of IKZF1/3, transcription factors foundational to multiple myeloma biology. Data from the Phase 1 trial, which has completed enrollment, show cemsidomide’s differentiated safety and tolerability pro potentially class-leading anti-myeloma activity that support the potential for durable outcomes. About the MOMENTUM Trial MOMENTUM (Multi-center trial Of cemsidoMidE iN relapsed/refracTory mUltiple Myeloma) is a Phase 2, open-label, single-arm, study to evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Data from the Phase 1 trial identified 100 µg as the recommended Phase 2 dose. The primary endpoint is overall response rate per International Myeloma Working Group response criteria, as assessed by an independent review committee. Approximately 100 patients who have received at least three prior anti-myeloma regimens that must have included an IKZF1/3 degrader, a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager or CAR-T therapy will be enrolled in the trial. More information is available at clinicaltrials.gov (NCT07284758). About Cemsidomide in Combination With Elranatamab (ELREXFIO ® ) The Phase 1b trial is designed to evaluate the safety, tolerability and preliminary efficacy of cemsidomide in combination with elranatamab, an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody. The study will evaluate different cemsidomide dose levels (beginning with 75 µg, with the opportunity to simultaneously explore 50 µg and 100 µg) in patients who have received one to four prior lines of therapy, which must have consisted of at least one IKZF1/3 degrader. Exclusion criteria for patients include those who have received prior treatment with a BCMA-directed T-cell engager or BCMA-directed CAR-T therapy. More information is available at clinicaltrials.gov (NCT07280013). About Multiple Myeloma Multiple myeloma (MM) is a rare blood cancer affecting plasma cells. Approximately 36,000 people in the United States are diagnosed with MM each year. Approved IKZF1/3 degraders remain foundational therapies across lines of MM treatment. Despite advances, including immune-directed approaches, most patients ultimately relapse, underscoring a growing need for new therapeutics options that continue to leverage IKZF1/3 degradation to drive myeloma cell death and T-cell activation. About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO ® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit . Forward Looking Statements This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO ® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC ® degraders; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement and patient enrollment; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our ability to replicate interim or early-stage results from our clinical trials in the results obtained when those clinical trials are completed or when those therapies complete later-stage clinical trials; regulatory developments in the United States and foreign countries; the anticipated timing and content of presentations of data from our clinical trials; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund our future operations will be available to us on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law. Contacts: Investors: Courtney Solberg Associate Director, Investor Relations CSolberg@c4therapeutics.com Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy LSpreen@c4therapeutics.com

Phase 1Phase 2ImmunotherapyDrug Approval

23 Feb 2026

·www.biospace.com

Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition

iStock, Mininyx Doodle The centerpiece of the takeover is anito-cel, a CAR T therapy under development for relapsed or refractory multiple myeloma. An FDA decision on the therapy is expected by December 2026. Just days after CEO Daniel O’Day told investors M&A was not an urgent priority for the pharma, Gilead is dropping $7.8 billion to swallow its CAR T partner Arcellx ahead of a potential approval later this year. Gilead’s offer values Arcellx at $115 per share, a 68% premium on the biotech’s volume-weighted average share price over the last 30 days, according to Gilead’s Monday announcement . The pharma has also tacked on a one-time nontransferable contingent value right that entitles Arcellx shareholders to $5 more per share that they hold, payable if a certain commercial milestone is hit. The companies expect to close the transaction in the second quarter of this year. Earnings Gilead To Stay ‘Proactive And Disciplined’ With Deals But M&A Not Urgent Priority With 10 launches planned in the coming quarters, Gilead isn’t feeling the same acquisition urgency as its pharma peers—though the prospect of a takeover isn’t off the table. February 11, 2026 · 2 min read · Tristan Manalac At the heart of Monday’s agreement is anitocabtagene autoleucel, also called anito-cel, an investigational CAR T therapy that targets the BCMA protein to treat relapsed or refractory multiple myeloma. The drug is currently under FDA review with a target action date of Dec. 23, 2026, Gilead said on Monday. Data from the pivotal Phase 2 iMMagine-1 study support the drug’s regulatory run. Results released in May 2025 demonstrated a 97% overall response rate , with complete response or stringent complete response reaching 68%. Progression-free and overall survival rates at six months were 91.9% and 96.6%, respectively. Gilead and Arcellx are also running the Phase 3 iMMagine-3 study, pitting anito-cel against standard of care, including pomalidomide, bortezomib and dexamethasone. The trial, which aims to enroll 450 patients with relapsed or refractory multiple myeloma who have undergone one to three prior lines of therapy, has a primary completion date of July 2028. The companies first linked up in December 2022, with the pharma through its Kite subsidiary fronting $225 million and making a $100 million equity investment into Arcellx. The agreement, which centered on anito-cel, also included a pledge of up to $3.9 billion in milestones. After almost a year, Gilead in November 2023 deepened its commitment to Arcellx for an additional $85 million in cash and $200 million in equity investments, plus the promise of unspecified milestones. Monday’s Arcellx acquisition follows a similarly hefty cell therapy contract in October 2025, when Gilead partnered with China’s Pregene for $120 million upfront and up to $1.52 billion in milestones. Then, in January, the pharma put $300 million on the line to collaborate with Texas-based OncoNano Medicine on developing novel cancer drugs.

Phase 3Clinical ResultAcquisitionCell TherapyImmunotherapy

17 Feb 2026

·www.prnewswire.com

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions of Elektrofi's Hypercon™ Technology and Surf Bio's Hyperconcentration Technology Reiterating 2026 Financial Guidance Ranges: Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30% Adjusted EBITDA of $1.125 - $1.205 billion, YOY Growth of 71% - 83%1 Non-GAAP Diluted EPS of $7.75 - $8.25, YOY Growth of 87% - 99%1 SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and fourth quarter ended December 31, 2025, and provided an update on its recent corporate activities. "2025 was a pivotal year for Halozyme as we delivered record total revenue of $1.4 billion, which was the result of continued growth in our ENHANZE business. In addition, we expanded our drug delivery technology portfolio with two acquisitions. Three ENHANZE‑enabled blockbusters, DARZALEX SC, Phesgo and VYVGART Hytrulo, drove royalty revenue growth of 52%, reaching a record $868 million in 2025. In the year, we also expanded our ENHANZE opportunities, adding three new collaboration and licensing agreements with Takeda, Merus and Skye Bioscience and gained one new target nomination from Roche. Furthermore, Janssen expanded the global reach of ENHANZE with approvals in the U.S., China and Japan for Rybrevant SC and new indication approvals in front line settings for DARZALEX Faspro. In parallel, we broadened our drug delivery portfolio with the acquisitions of the Hypercon technology and Surf Bio's hyperconcentration technology, which meaningfully expand, diversify and extend our long‑term royalty opportunity into the mid-2040s," said Dr. Helen Torley, President and Chief Executive Officer. Dr. Torley continued, "As we look ahead, our long-term outlook reflects the strong momentum and opportunity we have built through a broader drug delivery portfolio and offering to the biopharma industry. With royalty revenue projected to exceed $1 billion in 2026 and a clear line of sight to more than $2 billion in total revenue by 2028, Halozyme is entering its next phase of growth with strong conviction. Our projected 22% to 30% total revenue growth in 2026, combined with an expanding development pipeline with six projected new ENHANZE and two Hypercon development program starts, plus plans to sign three or more ENHANZE and Hypercon partnerships in 2026, all reinforce the durability of our revenue. With our strong cash generation and a diversified set of high‑value royalty drivers, we remain focused on delivering sustained long‑term value for shareholders." Fourth Quarter and Recent Corporate Highlights: In December 2025, Halozyme completed the acquisition of Surf Bio, Inc. ("Surf Bio"), subsequently renamed Halozyme Surf Bio, Inc., resulting in an expansion of Halozyme's drug delivery technology portfolio and the potential for future growth through new collaboration agreements. In December 2025, Halozyme announced that a German court had granted Halozyme's request for a preliminary injunction ordering Merck Sharp & Dohme Corp. ("Merck") to refrain from distributing and offering Keytruda® SC in Germany. In November 2025, Halozyme completed the acquisition of Elektrofi Inc. ("Elektrofi"), subsequently renamed Halozyme Hypercon, Inc., resulting in an expansion of Halozyme's drug delivery technology portfolio and the potential for future growth through new collaboration agreements. In November 2025, Halozyme completed the sale of $750.0 million aggregate principal amount of the 2031 Convertible Notes and $750.0 million aggregate principal amount of the 2032 Convertible Notes. The Company used a portion of the net proceeds to fund the cost of entering into the 2031 Capped Call Transactions and the 2032 Capped Call Transactions. The Company also used a portion of the net proceeds to enter into privately negotiated agreements with certain holders of its outstanding 2027 Convertible Notes and 2028 Convertible Notes to repurchase their 2027 Convertible Notes and 2028 Convertible Notes for cash through privately negotiated transactions entered into concurrently with or shortly after the offering. In November 2025, Halozyme entered into an amendment to the Company's credit agreement that, among other things extended the maturity date and increased the borrowing capacity of the Company's existing revolving credit facility from $575.0 million to $750.0 million. Fourth Quarter and Recent Partner Highlights: In January 2026, Janssen announced the U.S. Food and Drug Administration ("FDA") approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone ("D-VRd") for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. In December 2025, Halozyme and Skye Bioscience entered into a non-exclusive global collaboration and license agreement that provides Skye Bioscience access to ENHANZE® for the development and potential commercialization of an SC formulation of nimacimab for the treatment of obesity. In December 2025, Halozyme and Takeda entered into a new global collaboration and exclusive license agreement which provides Takeda with access to ENHANZE® for use with vedolizumab, marketed globally as ENTYVIO®, for the treatment of adults with moderately to severely active Crohns' disease or ulcerative colitis, which are the two main forms of inflammatory bowel disease. In December 2025, Roche nominated a new undisclosed non-exclusive target to be studied using ENHANZE®. In the fourth quarter of 2025, the ongoing argenx ARGX-121 Phase 1 program was expanded to include an SC-arm evaluating ARGX-121 with ENHANZE® in healthy adults. In December 2025, Janssen announced the FDA approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) for the treatment of patients with epidermal growth factor receptor ("EGFR")-mutated locally advanced or metastatic non-small cell lung cancer ("NSCLC"). In December 2025, Janssen received approval from the National Medical Products Administration in China for RYBREVANT™ FASPRO for the first-line treatment of adult patients with advanced NSCLC. In December 2025, Janssen received approval from the Ministry of Health, Labour and Welfare in Japan for RYBROFAZ® (amivantamab) with ENHANZE® for the first-line treatment of adult patients with advanced NSCLC. In December 2025, Halozyme entered into a commercial license and supply agreement with Viatris under which Halozyme licenses and supplies an auto-injector product for self-administered SC selatogrel for the treatment of acute myocardial infarction in adult patients. In November 2025, Janssen announced the FDA approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) co-formulated with ENHANZE®, as single treatment of adult patients with high-risk smoldering multiple myeloma. In November 2025, Halozyme and Merus entered into a non-exclusive global collaboration and license agreement that provides Merus access to ENHANZE® technology for a single target. Merus intends to explore development and potential commercialization of SC administration of petosemtamab, an EGFR and leucine-rich repeat-containing G-protein coupled receptor 5 bispecific antibody, for the treatment of head and neck cancer. Full Year and Fourth Quarter 2025 Financial Highlights: Total revenue for the full year was $1,396.6 million, compared to $1,015.3 million in 2024. The 38% year-over-year increase was primarily driven by royalty revenue growth and an increase in product sales. Revenue included $867.8 million in royalties, an increase of 52% compared to $571.0 million in 2024, primarily driven by continued sales uptake of ENHANZE® partner products that have launched since 2020, predominantly by VYVGART® Hytrulo by argenx, DARZALEX® SC by Janssen and Phesgo® by Roche in all geographies. Cost of sales for the full year was $228.8 million, compared to $159.4 million in 2024. The increase in cost of sales was primarily due to an increase in product sales and labor allocation initiatives. Amortization of intangibles expense for the full year was $76.7 million, compared to $71.0 million in 2024. The increase in amortization of intangibles expense was due to the acquisition of Elektrofi in November 2025. Research and development expense for the full year was $81.5 million, compared to $79.0 million in 2024. The increase was primarily due to the acquisition of Elektrofi and Surf Bio, partially offset by lower compensation expense driven by resource optimization, labor allocation initiatives, and timing of planned investments in ENHANZE® related to the development of our new high-yield rHuPH20 manufacturing process. Selling, general and administrative expense for the full year was $207.1 million, compared to $154.3 million in 2024. The increase was primarily due to an increase in consulting and professional service fees, including litigation costs incurred in connection with a patent infringement litigation case, diligence and transaction-related costs incurred in support of the acquisition of Elektrofi and Surf Bio, and an increase in compensation expense. Net income for the full year was $316.9 million, compared to $444.1 million in 2024. Net Income included acquired in-process research and development ("IPR&D") expense of $284.9 million related to the Surf Bio acquisition in the fourth quarter of 2025. Adjusted EBITDA for the full year was $657.6 million, compared to $632.2 million in 2024.1,2 Adjusted EBITDA included acquired IPR&D expense of $284.9 million related to the Surf Bio acquisition in the fourth quarter of 2025. GAAP diluted earnings per share for the full year was $2.56, compared to $3.43 in 2024. Non-GAAP diluted earnings per share was $4.15, compared to $4.23 in 2024.1,2 GAAP and non-GAAP diluted earnings per share included an unfavorable impact of approximately $2.30 per share related to acquired IPR&D expense for the Surf Bio acquisition in the fourth quarter of 2025. Total revenue in the fourth quarter was $451.8 million, compared to $298.0 million in the fourth quarter of 2024. The 52% year-over-year increase was primarily driven by royalty revenue growth and an increase in product sales. Revenue included $258.0 million in royalties, an increase of 51% compared to $170.4 million in the fourth quarter of 2024, primarily driven by continued sales uptake of ENHANZE® partner products that have launched since 2020, predominantly by VYVGART® Hytrulo by argenx, DARZALEX® SC by Janssen and Phesgo® by Roche in all geographies. Net loss in the fourth quarter was $141.6 million, compared to net income of $137.0 million in the fourth quarter of 2024. Net loss included acquired IPR&D expense of $284.9 million related to the Surf Bio acquisition in the fourth quarter of 2025. Adjusted EBITDA in the fourth quarter was $21.9 million, compared to $195.8 million in the fourth quarter of 2024.1,2 Adjusted EBITDA included acquired IPR&D expense of $284.9 million related to the Surf Bio acquisition in the fourth quarter of 2025. GAAP diluted loss per share in the fourth quarter was $1.20, compared to GAAP diluted earnings per share $1.06 in the fourth quarter of 2024. Non-GAAP diluted loss per share was $0.24 compared to Non-GAAP diluted earnings per share of $1.26 in the fourth quarter of 2024.1,2 GAAP and non-GAAP diluted loss per share in the fourth quarter of 2025 included an unfavorable impact of $2.42 per share related to acquired IPR&D expense for the Surf Bio acquisition in the fourth quarter of 2025. Cash, cash equivalents, restricted cash and marketable securities were $145.4 million on December 31, 2025, compared to $596.1 million on December 31, 2024. The decrease was primarily driven by cash used for the Elektrofi and Surf Bio acquisitions and share repurchases, partially offset by the net proceeds from issuance of convertible notes and cash generated from operations. Financial Outlook for 2026 The Company is reiterating its 2026 financial guidance ranges, which were last updated on January 28, 2026. For the full year 2026, the Company expects: Total revenue of $1.710 billion to $1.810 billion, representing growth of 22% to 30% over 2025 total revenue, primarily driven by increases in royalty revenue and product sales from API. Revenue from royalties of $1.130 billion to $1.170 billion, representing growth of 30% to 35% over 2025. Adjusted EBITDA of $1.125 billion to $1.205 billion, representing growth of 71% to 83% over 2025, including new Hypercon™ and Surf Bio investment of approximately $60 million. Non-GAAP diluted earnings per share of $7.75 to $8.25, representing growth of 87% to 99% over 2025. The Company's earnings per share guidance includes new Hypercon™ and Surf Bio investment of approximately $60 million and does not consider the impact of potential future share repurchases. Table 1. 2026 Financial Guidance Webcast and Conference Call Halozyme will host its Quarterly Update Conference Call for the fourth quarter and full year ended December 31, 2025 today, Tuesday, February 17, 2026, at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed live with pre-registration via link: . The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit Halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience. Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and the Surf Bio hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. The development of the Surf Bio polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly and argenx. Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility. For more information, visit and connect with us on LinkedIn. Note Regarding Use of Non-GAAP Financial Measures In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), this press release and the accompanying tables contain certain Non-GAAP financial measures. The Company reports earnings before interest, taxes, depreciation, and amortization ("EBITDA"), adjusted EBITDA, Non-GAAP diluted earnings per share, Non-GAAP diluted shares, and guidance with respect to those measures, in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company calculates Non-GAAP diluted earnings per share excluding share-based compensation expense, amortization of debt discounts, intangible asset amortization, one-time items, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges, transaction costs for business combinations, severance and share-based compensation acceleration expenses, intellectual property litigation costs, inducement expenses related to convertible notes, and certain adjustments to income tax expense. The Company calculates Non-GAAP diluted shares excluding the dilutive impact of convertible notes which is used in calculating Non-GAAP diluted earnings. The Company calculates EBITDA excluding interest, taxes, depreciation and amortization. The Company calculates adjusted EBITDA excluding one-time items, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges, transaction costs for business combinations, severance and share-based compensation acceleration expenses and intellectual property litigation costs. Reconciliations between GAAP and Non-GAAP financial measures are included at the end of this press release. The Company does not provide reconciliations of forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in share-based compensation expense and the effects of any discrete income tax items. For the same reasons, the Company is unable to address the probable significance of the unavailable information. The Company provides Non-GAAP financial measures that it believes will be achieved; however, it cannot accurately predict all of the components of the adjusted calculations and the GAAP measures may be materially different than the Non-GAAP measures. The Company evaluates other items of income and expense on an individual basis for potential inclusion in the calculation of Non-GAAP financial measures and considers both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to the Company's ongoing business operations and (iii) whether or not the Company expects it to occur as part of the Company's normal business on a regular basis. Non-GAAP financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similarly titled measures presented by other companies. These Non-GAAP financial measures are not meant to be considered in isolation and should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP, and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its Non-GAAP financial measures, and the Company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures. The Company considers these Non-GAAP financial measures to be important because they provide useful measures of the operating performance of the Company, exclusive of factors that do not directly affect what the Company considers to be its core operating performance, as well as unusual events. The Non-GAAP measures also allow investors and analysts to make additional comparisons of the operating activities of the Company's core business over time and with respect to other companies, as well as assessing trends and future expectations. The Company uses Non-GAAP financial information in assessing what it believes is a meaningful and comparable set of financial performance measures to evaluate operating trends, as well as in establishing portions of our performance-based incentive compensation programs. Safe Harbor Statement In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the Company's financial performance (including the Company's expected financial outlook for 2026) and expectations for future growth, profitability, revenue durability, total revenue, royalty revenue, royalty revenue duration, EBITDA, Adjusted EBITDA, and non-GAAP diluted earnings-per-share, and shareholder value. Forward-looking statements also include future plans, objectives, expectations and intentions related to the acquisitions of Elektrofi and Surf Bio, such acquisitions' expected impact and contributions to the Company's and combined group's operations and financial results (including potential development and commercialization of partnered products and timing related to these events), as well as the expected benefits of the acquisitions. Forward-looking statements related to Elektrofi's and Surf Bio's intellectual property include expectations for length of patent terms and patent expirations and the expected impact such patents may have on the duration, durability and amounts of future royalty payments the Company may receive from licensing such intellectual property. Forward-looking statements regarding the Company's ENHANZE® drug delivery technology may include the possible benefits and attributes of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery and administration of higher volumes of injectable medications through subcutaneous delivery. Forward-looking statements regarding the Company's business may include potential growth and receipt of royalty and milestone payments driven by our partners' development and commercialization efforts, potential new clinical trial study starts and advancement of partnered development programs, regulatory submissions and product launches, the size and growth prospects of our partners' drug franchises, potential new or expanded collaborations and collaborative targets, and potential approvals of new partnered or proprietary products, and the potential timing of these events. These forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "preliminary," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including uncertainties concerning future matters such as market conditions, changes in domestic and foreign business, changes in the competitive environment in which the Company operates, the expected benefits of its acquisitions of Elektrofi and Surf Bio, unexpected early expiration or termination of the patent terms for the Company's drug delivery technologies, unexpected levels of revenues, expenditures and costs, unexpected results or delays in the growth of the Company's business, or in the development, regulatory review or commercialization of the Company's partnered or proprietary products, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, including under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". Except as required by law, the Company undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-333-7668 [email protected] Sydney Charlton Teneo 917-972-8407 [email protected] SOURCE Halozyme Therapeutics, Inc. 21% more press release views with Request a Demo

Phase 1License out/inDrug ApprovalAcquisition

100 Deals associated with Dexamethasone Sodium Phosphate

External Link

KEGG	Wiki	ATC	Drug Bank
D00975	Dexamethasone Sodium Phosphate	D07AB19 H02AB02 D10AA03	DB01234

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Brain Edema	Austria	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Belgium	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Bulgaria	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Croatia	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Czechia	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Denmark	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Finland	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Germany	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Hungary	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Iceland	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Ireland	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Italy	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Netherlands	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Norway	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Poland	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Portugal	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Romania	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Slovakia	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Slovenia	Hameln pharma Gmbh.	28 Apr 2021
COVID-19	Austria	Hameln pharma Gmbh.	28 Apr 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 3	United States	TLC BioSciences	26 Nov 2019
Osteoarthritis, Knee	Phase 3	United States	Taiwan Liposome Co., Ltd.	26 Nov 2019
Osteoarthritis, Knee	Phase 3	Australia	TLC BioSciences	26 Nov 2019
Osteoarthritis, Knee	Phase 3	Australia	Taiwan Liposome Co., Ltd.	26 Nov 2019
Radicular Pain	Phase 3	United States	Scilex Pharmaceuticals, Inc.	08 Dec 2017
Radiculopathy	Phase 3	United States	Scilex Pharmaceuticals, Inc.	08 Dec 2017
Ataxia Telangiectasia	Phase 3	United States	Quince Therapeutics, Inc.	02 Mar 2017
Ataxia Telangiectasia	Phase 3	Australia	Quince Therapeutics, Inc.	02 Mar 2017
Ataxia Telangiectasia	Phase 3	Belgium	Quince Therapeutics, Inc.	02 Mar 2017
Ataxia Telangiectasia	Phase 3	Germany	Quince Therapeutics, Inc.	02 Mar 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02389517 (CTgov)	Phase 2	Multiple Myeloma \| Residual Neoplasm	42	Lenalidomide+Ixazomib Citrate+Dexamethasone (Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone))	ttacjmsboo = wnaumvrzvp edyisrnosq (qmhifmvlta, dyrkgfmpso - thllopmhiv) View more	-	22 Jan 2026
				Lenalidomide (Arm II (Lenalidomide))	ttacjmsboo = wvohlwqbid edyisrnosq (qmhifmvlta, zcawmhmuhy - syxwqfiihp) View more
NCT06006624 (Pubmed \| Orthop J Sports Med)	Phase 4	-	131	Liposomal bupivacaine	hboyiohuss(sqmofpmhsq) = ohwmokhlut zxtvknpuzv (jzhnlhzvbw, 21.9)	Positive	01 Jan 2026
				Liposomal bupivacaine + dexamethasone	hboyiohuss(sqmofpmhsq) = mhuapycguh zxtvknpuzv (jzhnlhzvbw, 14.33)
NCT03389620 (CTgov)	Phase 2	Radiculopathy	74	dexamethasone (Transforaminal Cervical Epidural Corticosteroid Injections)	hkllymkohy(odjbslaakt) = yqvvgjbifu kgjposdjgw (bxedxnjgkr, 2.50) View more	-	19 Dec 2025
				dexamethasone (Lateralized Interlaminar Epidural Corticosteroid Injections)	hkllymkohy(odjbslaakt) = vexjbzrogy kgjposdjgw (bxedxnjgkr, 2.20) View more
NCT03010202 (PROLONG, ASH2025)	Phase 2	Purpura, Thrombocytopenic, Idiopathic	127	Rituximab	iyweaqsakk(pcahtyrijk) = dcdoshhocr bipothmfps (xabumkdsvn ) View more	Positive	06 Dec 2025
				Rituximab+Dexamethasone	iyweaqsakk(pcahtyrijk) = hkgywwixpi bipothmfps (xabumkdsvn ) View more
ASH2025	Not Applicable	Refractory Multiple Myeloma	21	Aponermin + Carfilzomib + Pomalidomide + Dexamethasone	pabiddvzjq(bzmjlqbzgn) = yfgbuazoet roaypuolqu (kxplaxgyjz, 43.0 - 85.4) View more	Positive	06 Dec 2025
BIG-1 (ASH2025)	Phase 3	Acute Myeloid Leukemia Consolidation	220	High-dose cytarabine	faphvleuvs(qhmbqopiha) = vvlvftbocb vntqiphgxz (ghyfdmlpml, 36 - 56) View more	Negative	06 Dec 2025
				High-dose cytarabine+dexamethasone	faphvleuvs(qhmbqopiha) = viabeqmvep vntqiphgxz (ghyfdmlpml, 29 - 49) View more
ASH2025	Not Applicable	Purpura, Thrombocytopenic, Idiopathic First line	103	Dexamethasone and Eltrombopag (DE)	vymnnnipzv(wicuwhcyvo) = uuncssgest gwbzluoqvs (zjsunydujs ) View more	Positive	06 Dec 2025
				Dexamethasone, Eltrombopag and Azathioprine (DEA)	vymnnnipzv(wicuwhcyvo) = kdrtldlhzb gwbzluoqvs (zjsunydujs ) View more
ASH2025	Not Applicable	Primary Central Nervous System Lymphoma First line	63	R-MIAD regimen (rituximab, methotrexate, ifosfamide, cytarabine, dexamethasone)	pxpucmsrbj(ooicktpumy) = the incidence of grade 3-4 neutropenia, anemia, and thrombocytopenia being 46%, 3.2%, and 17.5%, respectively. All AEs were manageable; with no grade 4 non-hematologic AEs were observed. Only 7(11.1%) cases were observed with grade 3 non- hematological adverse reactions, and recovered well after treatment. eprclshcwh (vndljgjxco ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Purpura, Thrombocytopenic, Idiopathic First line	226	Dexamethasone 40 mg daily for 4 days with additional courses as needed	upxgnjrsix(frkodadpid) = phmhfhrzbc xjeqtbsdft (shhacvxnpc, 27.3 - 47.9) View more	Negative	06 Dec 2025
				Prednisone with tapering down	upxgnjrsix(frkodadpid) = oiqtljkzsc xjeqtbsdft (shhacvxnpc, 6.8 - 18.7) View more
GEM-CESAR (ASH2025)	Phase 2	Smoldering Multiple Myeloma	90	Daratumumab+ Pomalidomide +Dexamethasone (DPd)	wbekevelvm(biodfvkcwc) = kuueccswke xlukcrpdui (khduhrwvva ) View more	Positive	06 Dec 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis